BCR and neoplasm: In CLL, the BCR signaling pathway is constitutively activated, in immunoglobulin heavy-chain variable (IGHV) mutated cases in particular (5), and the anti-tumor effect of BTKis firstly depends on the direct inhibition of BTK (6).